I don't agree that it even looks good on paper. There is only **broken link removed** behind the commercialisation of the extract of the cyanobacterium Aphanizomenon flos-aquae and that solitary study was partially funded by a company that harvests Aphanizomenon flos-aquae and co-authored by someone with a direct financial interest in the extract. Also, that study was based on a tiny sample of initially 12 people which was reduced to 9. This alone would limit its generalisability. Furthermore, the 9 individuals demonstrated "[a] transient... increase in numbers of circulating CD34+ stem cells [that] maximized 1 hour after consumption [of the extract]". Is a 25% short-lived increase in CD34+ stem cells therapeutically significant? The company's marketing material is silent on is whether this transient, one-hour long increase in circulating CD34+ stem cells is therapeutically significant.
A 30-day supply of the extract will set you back **broken link removed**. That's pretty steep for a product with no proven value.